Highlights of the Annual Scientific Meeting of the Heart Failure Society of America 2016
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
The 20th annual meeting of the Heart Failure Society of America (HFSA) (September 17–20, 2016), held in Orlando, Florida, assembled multidisciplinary teams of clinicians and scientists for a thrilling journey of high-quality patient-centered care, an emerging theme of implementation science and trial interpretation.
Two trials of the vasopressin antagonist Tolvaptan in the setting of hospitalized heart failure (HF), and 2 separate applications of palliative care in advanced stage HF, debuted at the meeting. The aquaretic Tolvaptan was studied in the TACTICS (Targeting Acute Congestion With Tolvaptan in Congestive HF Study) and SECRET of CHF (Study to Evaluate Challenging Responses to Therapy in …